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Catanioinic surfactant vesicles have been explored as suitable drug carriers 
due to their similarities to phospholipids. Great strides have already been made in 
developing phospholipids for drug delivery and several liposomal drugs are already 
on the market. However, due to their inherent instability suitable alternatives have 
been explored. Herein six methods for the preparation of catanioinic surfactant 
vesicles containing sodium dodecylbenzylsulfonate (SDBS), 
cetyltrimethylammonium tosylate (CTAT), and glycoconjugate is explored. Four of 
the six methods were determined to produce vesicles with an average hydrodynamic 
radius of 76 nm. These vesicles have been shown to be to environmental changes to 
pH and ionic strength with no discernible difference based on preparation method.  
Also discussed is work down towards the development of a multilamellar 
vesicle system based on the functionalized catanionic surfactant system. Larger 
vesicles were able to be obtained, however were unable to systematically and 
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Chapter 1: History of the Field 
Introduction 
Advancements in technology and methodology have produced a wide array of 
medicinal chemicals previously unattainable. Many of these compounds demonstrate 
much promise during the initial trial phases only to be abandoned due to poor 
solubility, high toxicity, or inadequate selectivity. Attempts to circumvent these 
hindrances usually involve additional structural modifications. However, such 
changes often alter the lead molecules desired pharmacological effect. For example a 
hydroxy group may be added in order to decrease the lipophilic character of a drug; 
this change could however decrease circulation time through elimination by a new 
metabolic pathway. This small change also introduces a new site for hydrogen 
bonding which could interfere with binding in the active site.
1
 
The use of nanoparticles for drug delivery has been found to overcome many of these 
shortcomings. Nanoparticle formulations are known to improve the solubility of 
lipophilic drugs, improve the pharmokinetics, and improve the selectivity.
2
 Further 
enhancements of nanoparticles have also permitted environmentally stimulated 
release, sustained release, and combinatorial delivery of synergistic drugs.
2
 
Liposomal based nanoparticles were the first to obtain the approval from the Federal 
Drug Administration (FDA) for clinical use. Doxil, a polyethylene glycosylated 
(PEGylated) liposome carrier loaded with the cytotoxic anti- cancer drug 
doxorubicin, was approved in 1995. Free doxorubicin indiscriminately diffuses into 
healthy and diseased tissues alike, thus having a high toxicity. However, Doxil 
 2 
 




Due in part to this early discovery, liposomes are perhaps the most widely and well-
studied of all therapeutic nanoparticles.  Liposomes make suitable drug carriers since 
they are effectively able to encapsulate both hydrophilic and hydrophobic drugs. 
Several examples within literature demonstrate the ability of liposomes to act as drug 
carriers with 11 such drugs currently on the market(Table 1).
2–4
 Liposomes have also 
been shown to function as imaging agents and biosensors.
5,6
 Despite their obvious 
advantages the non-spontaneous formation and long term instability are major 
shortcomings that have remained unresolved. Conversely, ionic surfactant vesicles 
are known to spontaneously form unilamellar vesicles which demonstrate long term 
stability.  
Table 1: List of liposomal drugs that have been approved or are currently in development 
Name Indication 
Abelcet Fungal infections 
AmBisome Fungal and protozoal infections 
DepoCyt Malignant lymphomatous meningitis 
DaunoXome HIV-related Kaposi’s sarcoma 
Myocet Breast cancer (in combination with 
cyclophosphamide) 
Epaxal Hepatitis A 
Inflexal V Influenza 
DepoDur Postsurgical analgesia 
Visudyne Age-related macular degeneration, pathologic 
myopia, ocular histoplasmosis 
Doxil/ Caelyx HIV-related Kaposi’s sarcoma, metastatic breast 
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cancer, metastatic ovarian cancer 
Estrasorb Menopausal therapy 
MCC-465 Metastatic stomach cancer (Phase 1) 
MBP-426 Advanced or metastatic solid tumors(Phase 1/ 2) 
SGT-53 Solid Tumors (Phase 1) 
Liposome Based Drug Delivery 
The discovery of liposomes and the methodology for their development is credited to 
Dr. Bangham. In 1963 Dr. Bangham discovered that when dispersed in water, 
phospholipids formed closed, multilayered aggregates. Phospholipids are comprised 
of a charged hydrophilic head and two aliphatic hydrophobic tails. When placed in an 
aqueous medium they orient themselves in a bilayer fashion so that the polar heads 
interact with the water while the tails are hidden from the water. Due to their 
remarkable similarity to the cell membrane, liposomes were initially studied as 
artificial cell membranes. However, later research demonstrated their ability to 
encapsulate materials and their utility for drug encapsulation was studied.  
 As aforementioned, the basic structure of liposomes consists of a closed 
phospholipid bilayer which creates a spherical entity. The formation of such vesicles 
in vivo is quite common as part of many cellular processes such as the transport of 
molecules or sequestering of nutrients.  However, in vitro this formation is not 
spontaneous and thus requires some form of mechanical energy input for formation 
(Figure 1).
7
 The original method described by Bangham involved dissolving the 
phospholipids in an aqueous media followed by sonication to induce liposome 
formation. The majority of modern liposome synthesis methods involve drying lipids 
from organic solvents followed by dispersion into an aqueous media. This dispersion 
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is then followed by one of a variety of purification techniques such as extrusion, 
freeze-thaw, and reverse-phase evaporation. This leads to the creation of liposomes 
with vast differences in size, lamellar formation, and encapsulation efficiency.  
 
Figure 1: Synthetic scheme of phosphatidylcholine (PC) based liposome.  
Phospholipid is dispersed in aqueous media and the treated with mechanical energy (i.e. 
extrusion) in order to induce spherical bilayer formation  
 
 Given the wide array of preparation methods and encapsulation efficiencies of 
liposomes, a great deal of time and effort has gone into their development for 
therapeutic use. As previously mentioned, Doxil was the first liposomal drug carrier 
approved by the FDA. Doxil was developed as a treatment for Kaposi’s Sarcoma, 
which usually afflicts AIDS patients. It is the pegylated liposome encapsulated form 
of doxorubicin. The liposomal encapsulation of doxorubicin has been found to change 
its pharmacological profile. First, the circulation time of Doxil is increased due to the 
lowered renal clearance of liposomes. Secondly, due to the size of the liposomes the 
ability of doxorubicin to enter tissues with smaller gap junctions i.e. cardiac tissue is 
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decreased resulting in a lowered cardiotoxicity. The, encapsulation also slowed the 
release of free doxorubicin into the body resulting in a lower overall toxicity. Finally, 
due mainly to the enhanced permeability and retention effect (EPR) there was a 
greater distribution of Doxil into tumor sites when compared to free doxorubicin.
8–11
 
Since 1995 many more liposomal drug systems have made it through FDA approval 
and even more are in current clinical trials.
6
 
 While liposomes have demonstrated the ability to effectively encapsulate and 
deliver drugs they still suffer from major drawbacks. These drawbacks include their 
inherent long-term instability, tendency to aggregate, expense, and complicated 
formation methods. The latter two of these drawbacks are inherent to the materials 
used for liposomal formation (phospholipids) and thus cannot be easily changed. 
However, the first two of these drawbacks are directly correlated to the metastable 
nature of liposomes. Liposomes are thought to contain an excess of energy which 
leads to breakdown into more stable bilayers over time.
7,12,13
 Attempts to minimize 
these shortcomings include the addition of stabilizing additives to the bilayer and 
structural changes to the phospholipid components; however, a universal solution has 
not been seen.  
  An alternative liposomal technology is niosomes. Niosomes are comprised of 
single-tailed uncharged surfactant molecules which are capable of arranging 
themselves in a bilayer when prepared under the right conditions.
14
 It has been 
demonstrated that niosomes are capable of behaving like liposomes including the 
entrapment of solutes, bilayer formation, and controlled drug delivery.
6,14,15
 However, 
unilike liposomes, they are resistant to aggregation, inexpensive, and have a wider 
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array of principle components. Yet, since their preparation method is analogous to 
that of liposomes, niosomes suffer from the same metastable thermodynamics that 
make long term shelf-life a problem.  
Despite the ubiquitous usage of liposomal technology for drug delivery, there remains 
a great need to improve upon their inherent disadvantages. Many have focused on 
improving or attempting to eliminate these problems; whereas others have sought 
suitable replacements such as niosomes. One such suitable alternative that will be 
explored here is the use of catanionc surfactant vesicles.  
Catanionic Surfactant Vesicles 
In 1989, Kaler and co-workers presented a simple alternative to liposomal 
technology. The method presented the formation of vesicles from single-tailed 
charged surfactants. When mixed in defined proportions these surfactants formed 
bilayers analogous to those formed by phospholipids. The size of the vesicles varied 
(radius between 30-80 nm) according to the molar ratios of the surfactants to each 
other as well as the %wt of water.
16
 The novelty of this system derives from the 
inexpensive components, ease of preparation, and remarkable similarity to lipisomal 
bilayers. Following the work of Kaler, other groups divulged the various capabilities 
and properties of the surfactant vesicle system.  
 The formation of the bilayer from surfactants was found to require that one of 
the charged surfactants be present in an excess molar amount to the other. Further 
inquiry into vesicle formation elucidated properties which controlled vesicle 
formation such as the alkyl chain length and area of the head group.
13,17–21
  Unlike the 
formation of liposomes, surfacant vesicle formation is simple and spontaneous. 
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Addition of water to the solid surfactants followed by gentle mixing causes vesicle 
formation. (Figure 2) The lack of a need to input energy in order induce vesicle 
formation is believed to increase the stability of the system when compared to the 
metastable liposomal systems. Though whether or not theses vesicle formations are 
truly thermodynamically stable is an area of contention.  
 
Figure 2: : Spontaneous formation of catanionic surfactant vesicles. Water is added to solid 
surfactants followed by gentle stirring resulting in spontaneous vesicle formation 
Aforementioned, was the requirement for definite proportions needed for the vesicle 
formation. Kaler found that vesicle formation was constrained by; surfactant ratios to 
each other, asymmetry of the aliphatic tails, and total wt % of the surfactants in 
solution. Vesicle formation is believed to be the result of unique pairing of the ionic 
surfactants. Studies performed by Kaler, Regev, and others have elucidated the 
geometric constraints of the vesicle formation.
20,22–24
 They found that formation of 
vesicles could be explained through the packing parameter (Figure 3). Packing 
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parameter is defined as the ratio between the volume of the hydrophobic region to 
area of the polar head group combined with the optimal chain length of the aliphatic 
chain.  
 
Figure 3 Packing parameter equation. Where P is the packing parameter v is the 
hydrophobic volume, a0 is the polar head group area and l is the optimal chain length. 
  
 
Figure 4 Resulting structures from changes in packing parameter. 
Figure 4 depicts the various shapes that can be obtained by changing the various 
aspects of the packing parameter. Manipulating the various aspects of the packing 
parameter directly affects the type of packing shape the individual molecules form 
and thus the structures they assemble into For example the headgroup area of anionic 
surfactants can be made smaller by increasing the salt concentration or lowering the 
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pH; the chain length (l) can be decreased by introducing unsaturation.
25
  In the case of 
catanionc vesicles it is proposed that when one surfactant is present in excess to the 
other it results in a zwiterronionic pairing. This pairing into a zwiterronic molecule 
decreases the area of the polar head group while simultaneously increasing the area of 
the hydrophobic region; effectively creating the truncated cone shape characteristic of 
double-tailed phospholipids opposed to the traditional wedge expected from single 
tailed surfactants. Thus, at these concentrations it becomes more energetically 
favorable to spontaneously form vesicles as opposed to infinite bilayers.  
           Following the initial work of Kaler, other groups built upon this work in order 
to study the various properties of vesicles and their comparability to liposomes. The 
main areas of focus were functionalization, encapsulation efficiency, and stability  
Encapsulation efficiency is of utmost importance in for surfactant vesicles to function 
as suitable drug carriers. Along with the initial report of vesicle formation, Kaler 
reported the ability of both anionic and cationic vesicles made from 
cetyltrimethylammonium tosylate and sodium dodecylbenzyl sulfonate (CTAT/ 
SDBS) to effectively encapsulate glucose within their aqueous compartments. 
However, the amount of glucose encapsulated by the vesicles was not reported at the 
time. Subsequent studies by Calliet using sodium octyl sulfate (SOS) and 
cetyltrimethylammonium bromide (CTAB) demonstrated the ability of anionic 
vesicles to encapsulate approximately 1% of the glucose introduced to the system.
17
  
Further study into the encapsulation efficiency of SDBS/ CTAT was undertaken by 
Danoff et. al.
26
  Their study involved measuring the encapsulation of five organic 
solutes which possessed a charge. It was reported that while both vesicles (anionic 
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and cationic) were capable of capturing the organic solutes, maximum encapsulation 
efficiency was obtained when the solute and vesicle possessed opposing charges. This 
resulted in encapsulation efficiencies ranging from 22-74%.
26
 Furthermore, in the 
case of the anionic dye carboxyflourecein, the vesicles where reported to be stable for 
114 days. This development demonstrated the ability of the SDBS/CTAT vesicle 
system to encapsulate various solutes while maintaining a reasonable stability; 
important criteria for potential drug carriers.
27
 
         It has been demonstrated that liposomes can be functionalized in order to 
improve their association and therefore target specific sites. Groups such as 
Letourneur have shown that liposomes coated with modified dextrans have an 
increased affinity to human endothelial and smooth muscular vascular cells. Similar 
functionalization has also been demonstrated with surfactant vesicle systems. Walker 
reported the mixing of CTAT, SDBS, and phospholipid linked biotin to form surface 
functionalized cationic vesicles. Aggregation of the vesicles was observed upon 
addition of streptavidin.
28
 Wang has also shown that the surfaces of ionic surfactant 




Work within the DeShong group has demonstrated the ability of catanionic vesicles to 
be functionalized by carbohydrates.
29,30
 Lectin-carbohydrate interactions play a part 
in various biological processes including immune response, pathogenic infections, 
and reproduction. Though the interactions of proteins and carbohydrates are typically 
weak, their affinity is increased through multivaleancy. These multivalent interactions 
have been shown to increase the affinity of these interactions a hundred fold. One of 
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the most studied interactions has been that of concanavalin A (ConA). ConA binds to 
glucose, mannose, sucrose, and other carbohydrates. In fact, ConA glucose binding is 
one the strongest interactions known. It is possible for ConA  to exist in two forms; 
the dimer at pH 5.5 and the tetramer at pH’s greater than 7. The tetramer contains 
four glucose binding sites which allow ConA to bind in a multivalent fashion.  Park 
and co-workers have reported functionalizing catanionic surfactant vesicles using 
glycoconjugates of varying alkyl chain lengths.   The glycoconjugate functionalized 




At this point it has been demonstrated that surfactant vesicles are suitable 
nanoparticle candidates for drug delivery. Furthermore, they have been shown to have 
several advantages over the ubiquitously used liposomal technology which is 
summarized in Table 2. However, there remain several questions about the catanionic 
system which will be presented and discussed herein.               
 
Figure 5 Lectin induced vesicle aggregation.  Aggregation of glycoconjugate 





Table 2: Comparison of Surfactant Vesicles to Liposomes 
 
Specific Aims 
If catanionic vesicle are to be employed effectively for biomedical applications such 
as targeted drug delivery, the properties and stability of these formulations must be 
determined. Accordingly, my thesis research was to asses a series of stability 
parameters of catanionic vesicle preparation methods. The specific aims for this 
research were to: 
1. Evaluate potential differences in the methods used to create functionalized 
unilamellar vesicles. We proposed to study: 
a. The size and dispersity of vesicles as measured by dynamic light 
scattering (DLS) 
b. The stability of vesicles to pH 
c. The stability of vesicles to ionic strength 
d. The changes in surface charge (zeta-potential) as a function of 
increasing glycoconjugate concentration 
2. Expand the methods used for preparing unilamellar vesicles for the 
preparation of multilamellar vesicles 
 






Formation Spontaneous Sonication , Extrusion 
Stability 
Years at room temp (in 
saline) 
Days to weeks at room temp (in 
saline) 
Entrap Ionic Solutes Highly efficient Inefficient 
pH 2-12 6-8 
Sterilization Autoclavable Not autoclavable 
Heating 85 °C max 45 °C max 
Lyophilization Yes No 
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Chapter 2: Catanionc Surfactant Vesicles 
Introduction 
Previously, the changes to the pharmacological profile of doxorubicin upon 
encapsulation in a liposomal formulation were discussed. It has been well 
documented that many cancer focused nanodrugs benefit from the EPR effect 
(enhanced permeability and retention effect)
31,32
.  In order to sustain their rapid 
growth cancerous tumors stimulate the growth of blood vessels.  This increased 
vascularization along with other factors such as diminished lymphatics around tumor 
sites make nanoparticles more apt to permeate and be retained in cancerous tissues 
than in noncancerous tissues. This leads to a higher site specific dosage. However, the 
ability of nanodrugs to benefit from this effect is inherently tied to the physical 
properties of the nanodrug. These properties include the size, shape, charge, and 
stability of the nanoparticles. Due to their similarity to liposomes it is probable that 
catanionic surfactant vesicles will be able to benefit from the EPR effect as well. 
However, since there are various preparation methods there is the possibility for 
differences in the properties of the resulting vesicles. Therefore, it is imperative to 
discover if the various preparation methods change any of these properties and if so to 





Catanioinc Vesicle Preperation 
Initially functionalized vesicles were prepared using the three main variations of the 
Wang procedure: Method 1- mixing solid surfactant and the desired amount of 
glycoconjugate prior to addition of water; Method 2- preparing bare vesicles followed 
by addition to the desired amount of solid glycoconjugate; and Method 3- making a 
solution of the desired amount of glycoconjugate and adding it to the solid surfactants 
(Figure 6). In order to keep the total percent by weight (wt%) of surfactants and 
glycoconjugate at 1%the weight of solid surfactants was adjusted in concert with 
increasing weight of the glycoconjugate Three additional methods were also studied 
wherein the weights of the solid surfactants were kept constant and only the amount 
of glycoconjugate was changed. These methods are referred to as Method 4, Method 
5, and Method 6 respectively. The resulting colloid solutions for all six methods were 





Figure 6  Methods for synthesizing functionalized ULVs. (a) all the solid components were 
added to vial followed by addition of water to induce vesicle formation (Method 1 and 
Method 4) (b) water was added to solid surfactants in order to make bare vesicles. Vesicle 
solution was then added to solid C12-glucose to make functionalized vesicles (Method 2 and 
Method 5) (c) A solution of solubilized C12-glucose was added to solid surfactants to make 
functionalized vesicles (Method 3 and Method 6) 
Size 
Formation of vesicles and their average hydrodynamic radius was confirmed using 
dynamic light scattering (henceforth referred to radius and DLS respectively). All 
DLS measurements were taken at 25°C and a scattering angle of 90° using a Photocor 
Complex Optical unit equipped with a 5mW laser 633nm. The phenol-sulfuric acid 
assay of vesicle containing fractions further proved incorporation of the 
glycoconjugate into the vesicles. Previous work in our lab has demonstrated that 
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vesicles can be functionalized with various glycoconjugates. However, since three 
methods of preparation were used it was important to ensure that comparable amounts 
of glycoconjugate were incorporated into the vesicles. During the preparation of 
vesicles it was found that methods 3 and 6 were unable to dissolve the higher 
concentrations of the non-ionic C12-glucose. Thus, these methods were not available 
for further examination.   However, results from the phenol-sulfuric acid assay of the 
other methods indicate that regardless of the method there is a comparable amount of 
glycoconjugate incorporated into the vesicles. 
DLS results showed that there is a noticeable increase in size correlating to the 
increase of glycoconjugate loading among the four studied methods. Otherwise, all 
methods produced vesicles that had an average hydrodynamic radius of 72 nm ± 
10nm. This suggests that while the order of addition of the solid components does not 
have a significant effect on the size on the resultant vesicles the amount of 
glycoconjugate added does.  
Stability Studies 
Zeta Potential 
For colloidal systems, the measurement of the zeta potential will provide a good 
indication into the stability of the solution. Zeta potential measures the overall surface 
charge of the particle while in solution. Therefore, collodial solutions that have a 
large magnitude for the zeta potential will be less apt to aggregate and thus be more 
stable. This is due to the large increase in repulsion of the particles to each other. 
Conversely, a lower zeta potential will indicate a system that will more readily 
aggregate and thus be considered to be less stable.  For methods 1 and 2 there was a 
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slight decrease in the zeta potential as the loading of the glycoconjugate increased. 
However, this decreasing trend was absent for corresponding methods 4 and 5. For 
Methods 1 and 2 the amount of surfactant decreases as the amount of glycoconjugate 
increases. Conversely, with Methods 4 and 5 the amount of the surfactant remains 
constant as the amount of glycoconjugate increases. Thus, when comparing Methods 
1 and 4 the experimental conditions are identical except for the amount of the anionic 
surfactant SDBS; this is also true in the comparison of methods 2 and 5. Therefore, 
the overall decrease in the zeta potential for the vesicles prepared by Methods 1 and 2 
is due to the overall decrease in the amount of the anionic surfactant SDBS rather 
than the increase of the nonionic glycoconjugate. The zeta potential of the ULV 
systems all averaged -60 mV regardless of synthesis method, indicating a good level 
of stability.  
pH 
As aforementioned, the structure that is spontaneously formed by amphiphilic 
molecules is highly dependent on the packing parameter. Thus, any effect that will 
change the packing parameter will affect the stability of the formed vesicle structures. 
Since the optimal chain length and volume remain largely unaffected by changes in 
solution, the easiest factor to manipulate is  
the headgroup area. Since the headgroup is negatively charged, its area will relatively 
easily affected by changes in ionic strength and pH.  
It is well documented that cancer cells have a lower pH than the physiological pH of 
noncancerous cells. This has been accepted as a byproduct of the Warburg Effect. 
The Warburg Effect is the explanation for the alternative glycolysis route observed in 
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the cells of most clinical cancers. This route follows the fermentation of lactic acid 
rather than the oxidation of pyruvate observed in normal cells. Consequently, the rate 
of glycolysis in cancerous cells occurs at an accelerated rate, often 200 times more, 
than in normal cells.
33
 This increased rate of glycolysis is believed to be the one of 
the major causes for the acidification of cancerous cells. It is also believed that this 
acidification plays a role in the rapid proliferation of cancer cells. 
Various efforts have been made to exploit the pH difference between host and cancer 
cells in nanoparticle drug delivery research. The general strategy involves the use of 
acid labile linkers that bridge a protective group such as PEG to penetrating peptides, 
targeting agents, hydrophobically modified drugs, or a multifunctional combination 
of the above.
34–37
   One such example is work done by Lee et. al. In summary they 
developed a multifunctional polymer backbone of N-2-
(hydroxypropyl)methacrylamide (HPMA) with hydrazone linked doxorubicin  
(DOX). The hydrazone linkage was cleaved under the acidic conditions of the tumor 
environment thus delivering the free DOX directly to the site. This understandably 
increased the amount of DOX delivered to the site.
36
  
The study of effect of pH on the stability of our catanionic system was carried out for 
a several reasons. First, in order to develop possible pH induced triggers utilizing our 
catanionic surfactant vesicle system it is first imperative to study the stability of the 
vesicles under various pH conditions. Due to the acidic nature of tumors, nanodrugs 
that are basic or not viable in acidic environments will show a diminished benefit and 
thus result in a lower accumulation in the cancerous cells. Finally, pH is one of the 
factors that control the headgroup area. As aforementioned, changes to the headgroup 
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area will influence the packing parameter and thus the shape of the vesicles. Such 
changes could result in new substructures or different sized vesicles; both of which 
could have an impact on the circulation and retention times. Figure 7 shows the 
changes in radius as a function of pH. It can be seen that the radius of C12-glucose 
functionalized ULVs remains constant throughout a wide range of pH values in 
agreement with previous results given for bare ULVs.  
 





It is known that increasing the ionic strength of solution containing anionic liposomes 
will decrease the headgroup area and thus increase the size of the vesicles. Since 
catanionc vesicles behave differently from their liposomal counterparts, it was desired 
to determine the effect of ionic strength on the ULV systems. Each procedure 
introduced the glycoconjugate at different stages; thus, it was hypothesized that there 
would be variations in the overall distribution. This could in turn affect the ability of 
the vesicles to adjust to changes in ionic strength. If the differences in bilayer 
distribution were large enough it should result in varying responses to ionic strength.  
To test this theory the vesicles were added to solutions of varying salt concentration 
and the change in size was monitored by DLS (Figure 8). The ULV system 
demonstrated a rather uniform stability in terms of increasing the salt concentration 
with significant changes in size occurring when the salt concentration in excess of 
0.5M. This suggests that while the distribution of C12-glucose may be different 
dependent on the method, at this concentration it does not perturb the bilayer 
composition enough to cause any marked differences in stability to ionic strength.  
 
 




Cryogenic Transmission Electron Microscopy (Cryo-TEM) was used in order 
to confirm the sizes and presumed structures of the ULV system. The figure below 
shows that the vesicles do have a range of sizes as is expected from their spontaneous 
formation (Figure 9). Furthermore, the size of the vesicle confirms the prior results 
obtained from the DLS experiments. Most importantly, the vesicles obtained from the 
methods are shown to in fact be unilamellar systems.  
 
Glycoconjugate Distribution 
Based on the methods studied, it was hypothesized that there would be two distinct 
distributions of C12-glucose; for Methods 1 and 4, where the glycoconjugate is 
present as the vesicles are formed, there should be glycoconjugate present on the 
interior and exterior of the vesicles; whereas in Methods 2 and 5, where the vesicles 
are formed prior to adding the glycoconjugate, there should only be glycoconjugate 
on the exterior of the vesicles.  Previous work has established that the rate of binding 
is directly correlated to the concentration of C12-glucose (Figure 10); therefore, 
Figure 9 Cryo-TEM of Method 1 ULV 
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differences in the distribution of C12-glucose in the outer portion of the bilayer should 
affect rates of the binding kinetics.
30
 Systems with a higher distribution of C12-
glucose in the outer layer should result in a faster increase in the turbidity. Therefore, 
systematic kinetic studies at each concentration for all methods should be able to 
elucidate any differences in the distribution amongst these methods.  
 
Figure 10 As bilayer glucose concentration increases agglutination rates increase.
30
 
With the functionalized vesicles in a cuvette UV-Vis,  ConA was added to the 
vesicles and the change in absorbance continually recorded as a function of time for 
60 seconds. Immediate aggregation was observed within 1s of ConA addition for all 
concentrations of C12-glucose.  Figure 11 shows the normalized data from these 
experiments. This data shows that for the corresponding glycoconjugate 
concentrations the rates is agglutination between Methods 1 and Method 2 were 
comparable to each other. Likewise the agglutination rate between Method 4 and 
Method 5 were also comparable. This indicates that despite the preparation method, 
the distribution of the glycoconjugate in resultant vesicles are the same. However, the 
agglutination rates of Methods 1 and 2 were discernibly faster than that of Methods 4 






Figure 11 Kinetic Data 
 
Current Work 
It is well documented that the addition of cholesterol to liposomes can increase their 
stability presumably in the same manner in which cholesterol stabilizes cellular 
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structures. We sought to determine if the same would hold true for our catanionc 
system. We have been able to synthesize cholesterol-C12-glucose vesicles utilizing 
Method 1 with cholesterol loadings up to .02 mole fraction. These vesicles have 
demonstrated a comparable size to their non-cholesterol counterparts and are capable 
of aggregation upon addition of ConA.  Preliminary turbidity and DLS studies 
suggest that C12-glucose vesicles with added cholesterol show increased stability in 
regards to changes in ionic strength. A more in depth study covering the full range of 
stability studies of these vesicles will be explored. 
Conclusions 
Presented here is a description of six different methods for the preparation of  
C12-glucose functionalized ULVs. The inability to create solutions of the 
glycoconjugate at higher concentrations invalidated two of the proposed preparation 
methods, thus only four methods were studied further.  
The results from the phenol-sulfuric acid assay demonstrated that regardless of 
preparation method the amount of glucose associated with the vesicles remained the 
same. This suggests that while the order in which C12-glucose was added to the 
vesicles was different, that the majority of the glucose associated with the vesicles 
after SEC remained the same.  Additional characterization of the various preparation 
methods further confirms that the vesicles formed shared analogous stability and 
characteristics. The size of the resultant vesicles remained the same for the 
corresponding C12-glucose concentration. Furthermore, all four methods showed 
remarkable stability to a wide range of pH values as well as ionic strength.  
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The kinetic studies indicated that even at higher concentrations of the glycoconjugate 
there is no discernible difference in the distribution between the interior and exterior 
leaflet. This suggests that there is a preference for the glycoconjugate to be in the 
exterior leaflet of the vesicles. This is most likely due to the packing parameter and 
the shape of the glycoconjugate.   
Since has been shown that these four methods produce analogous vesicles any of 
them could be used for the preparation of vesicles for future drug delivery purposes. 
Furthermore, since the surfactant concentration can be kept constant without any 
adverse effects methods 4 and 5 can be used for the added ease of preparation.   
Future Work 
Loading Capacity 
Prior work within our group has demonstrated that varying amounts of C12-
glucose may be loaded into the catanionic surfactant vesicles loading up to 0.3 mol 
fraction.
29,30
 However, this work was performed on vesicles made by a procedure 
analogous to method 1 reported here.  Currently it is assumed that the three methods 
differ in the final location of C12-glucose in the bilayer based on the order of addition 
of the glucose (Figure 12). However, it is unknown whether the order of addition 
affects the overall loading capacity. At higher concentrations of C12-glucose 
differences distribution may have an effect on the maximum loading capacity. Thus, 
this research shall be expanded in order to elucidate any differences in the loading 
capacities of the three methods. The amount of glucose associated with the vesicles 
prepared by each method will be compared using the phenol-sulfuric acid assay. 
Previous results indicate a direct correlation between the results obtained from this 
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assay to the amount of glycoconjugate added to the vesicles (Figure 10).
29
  These 
studies will be expanded to other moieties specifically hydrophobicly modified folate.  
 
 
Figure 12 Plot of detected glucose (proportional to UV - vis signal of colorimetric 




Other members within the group have performed preliminary studies involving the 
loading of doxorubicin into our catanionic vesicles. This works has provided a broad 
range of loadings which have been used for successful mice studies. The maximum 
loading of doxorubicin has been estimated to be ~.02 mole fraction as evident by the 
precipitation of excess doxorubicin from the vesicles. However, a systematic study 
into the encapsulation efficiency, loading capacity, and characterization of these 
vesicles has not been performed. Thus, I will focus on exploring these aspects of 
doxorubicin loaded vesicles between the ranges of .01-.02 mole fraction.  
Utilizing the methods reported by others in the field, the encapsulation efficiency of 
vesicles will be measured. This may be done by directly measuring the amount of 
doxorubicin associated with the vesicle fractions as a ration to the amount of 
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doxorubicin initially loaded into the vesicles. The levels of doxorubicin can be 
monitored by the absorbance peak at 490 nm by UV-Vis. This systematic approach 
will permit a quantitative determination of the maximum load of doxorubicin that the 
catanionic system is capable of delivering. The resulting system(s) will be fully 
characterized in the same manner previously described. Finally, the creation of a 
multifunctional catanionic system will be studied by creating vesicles containing 
doxorubicin along with targeting molecules such as folate. Analogous work to that 
reported will be done to determine the optimal loading of each component, i.e. 





Chapter 3: Multilamellar Catanionic Surfactant Vesicles 
Introduction 
Prior to the advent of nanoparticles methods to increase solubility were 
limited to structural changes or changes in the formulation. Such methods often have 
adverse effects on the selectivity and toxicity of the desired therapeutic. 
Aforementioned were the various methods employed by nanocarriers to overcome 
these challenges. Liposomes in particular have been studied as drug carriers since 
they allow for the transport of both hydrophobic and hydrophilic molecules. 
However, since the therapeutic effect is highly dependent on the amount of drug 
delivered the encapsulation efficiency of drug molecules by liposomes is very 
important. Introduction of the desired pharmaceutical may change the properties of 
the bilayer, size, and charge of the carrier particle; all of which affects the inherent 
stability of the molecule. Thus a delicate balance must be made between stability of 
the nanocarrier and the payload delivery. As a result encapsulation efficiency remains 
one of the many challenges faced in the development of novel drug carriers.  
One of the methods used in increase the encapsulation efficiency of 
hydrophobic drugs within liposomal drug carriers is multilamellar liposomes. By 
increasing the amount of lamellae present the overall area of hydrophobic areas 
within the liposome is increased. This allows for a greater entrapment of the 
hydrophobic molecule within the bilayers. Theoretical experiments have calculated 
that the structures of multilamellar liposomes could provide some benefits such as 
greater stability with increasing lamellae and reduced stress due to osmotic shock.
38
 
However, outside of the theoretical calculations few reports of actual multilamellar 
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liposome used for drug delivery have been reported. This is due mainly to non-
uniformity in size, non uniform lamellarity, poor long term stability, and lack of a 
standard preparation.  
A more recent development within this field is the advent of DepoFoam 
(Figure 13). DepoFoam is described as being a unique liposomal drug release 
formulation that may be described as being a multivesicular system (MVL).
39,40
Each 
DepoFoam particle encloses multiple nonconcentric chambers each enclosed by a 
single lipid bilayer. This results in multiple aqueous and lipid areas in which 
molecules of interest may be encapsulated. Thus, as a result of the increased 
encapsulation there is a higher drug delivery to the targeted site. However, the 
enclosed multiple bilayers create slower and sustained release lowering the toxicity of 
the encapsulated drug while increasing the drug load.
39–43
 The development of 
DepoFoam technology has been used in of several FDA approved formulations such 
as DepoCyt and DepoDur which are used for the sustained release for cytabrine and 
morphine respectively.  
 
Figure 13 Transmission electron microscope (TEM) image of DepoFoam Particle. 
Multivesicular system consisting of a large spherical liposome containing many smaller 
spherical liposomes. 
Previously, it was mentioned that one of the advantages of the catanionic 
surfactant vesicle system over liposomes was the ease of reproducibly creating ULVs. 
 30 
 
Liposomal techniques all require some form of mechanical energy during their 
preparation, i.e. sonication or extrusion, in order to homogenize the system and create 
the metastable unilamellar system. The apparent absence of spontaneous 
multilamellar vesicle formation utilizing a process presents a unique challenge in 
creating additional hydrophobic sites for increased drug loading.  
During inquiry into the multivalent capabilities of surfactant vesicles, Dr. 
English serendipitously discovered that upon disaggregation, several of the vesicles 
were multilamellar in nature (Figure 14).
44
 We sought to explore this feature and 
develop a reproducible method of creating mulitlamellar vesicles hereto referred to as 
MLVs. Since the lamellae of these MLVs would be linked through a lectin-ConA-
lectin linkage it was believed that these vesicles should impart similar if not greater 
stability when compared to the ULV counterparts. Theoretically, initial hydrophobic 
loading could occur during the initial vesicle formation followed by an additional 
loading step after MLV formation. This would allow for increased loading of one 
drug or a possible tandem drug delivery system.  
 






Preparation of Multilamellar Vesicles 
In order to create MLVs, the C12 functionalized ULVs that were previously 
synthesized were treated with concanavalin A (ConA). In accordance with previous 
research, this resulted in immediate aggregation and a visible increase in turbidity. 
This aggregated colloid system was subsequently treated with a concentrated glucose 
solution effectively disaggregating the system (Figure 15). Finally, the presumed 
MLVs were purified by SEC using Sephadex 100-G saturated in glucose. Fractions 3 
and 4 were collected and vesicle formation was confirmed by DLS.  
 
Figure 15 Proposed synthesis of MLVs. ULV previously created were treated with ConA 





To compare the potential stability of the MLV system to the ULV system the zeta 
potential was once again obtained. Results showed that the zeta potential of the MLV 
system was significantly lower than that of the ULV system, averaging -30mV. Once 
again, there was only one population responsible for the potential correlating to the 
data obtained from DLS. The lower potential indicates that the MLV systems are less 
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resistant to aggregation than the ULV system and thus there may be a higher 
propensity for the system to aggregate overtime.  
Ionic Strength 
Like ULVs the packing parameter of the MLVs can be manipulated by changes in the 
ionic strength of the solution.  When the ionic strength containing MLVs was 
increased there a dramatic increase in size a lot earlier than that seen in the ULV 
system. Furthermore, complete dissolution of the MLV system occurred at a lower 
ionic strength as well. Once again this may be explained by the packing parameter. 
Since the size of the MLVs are larger than that of the ULVs. This means that the 
ability of the MLVs to rearrange in order to accommodate such changes is greatly 
diminished.  Interestingly, while all of the ULV preparations demonstrated a rather 
uniform response to changes in ionic strength in the MLV system the vesicles 
prepared by the VAM method demonstrated a marked difference.  
 




The prior results all indicate that the resulting solution formed after disaggregation 
behaves significantly different from the originally developed ULV system.  This 
suggested that the MLV system must have an inherent structural difference in order to 
account for these differences. As aforementioned, the results reported by English et. 
al.  demonstrated MLV vesicle formation after disaggregation of the ConA vesicles. 
Thus, it was expected that cryo-TEM images of our MLV system would show more 
of the same. However, Figure 17 shows that while larger vesicles are indeed formed, 
they are not multilamellar in nature. The TEM images below confirm that the vesicles 
in the MLV systems are larger. However, they fail to elucidate any other structural 
difference between the two systems. Thus, it would seem that the difference in 
behavior is due solely to the larger size of the vesicle system.  
 
Figure 17 Cryo-TEM of the MLV (Method 1 - multi shown) 
Dialysis 
The ability of the MLVs to be disaggregated by the addition of glucose piqued 
interest in the system being completely reversible. Therefore, it was believed that 
removal of the excess glucose concentration should result in the aggregation of the 
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system which could then again be disaggregated. Dialysis was determined to be the 
most suitable method to carry out this goal. Thus, when the disaggregated vesicles 
were subjected to dialysis the excess glucose was removed which resulted in the 
system aggregating. However, when these aggregated vesicles were treated with an 
equal amount of glucose the system failed to disaggregate again.  
 
 
Figure 18 Proposed reversible aggregation process. 
Conclusions 
Attempts to create a reproducible and systematic method for the preparation of MLVs 
were successful in producing larger vesicles. These larger vesicles were more 
sensitive to environmental changes and demonstrated a lower zeta-potential. This 
indicated that they are most likely less stable than their ULV counterparts. This 
marked decrease in stability indicates that these larger vesicles are close to the critical 
size for the given surfactant system. Thus, they are unable to accommodate 
environmental changes that would affect the packing parameter by increasing their 
size.  These MLVs are not fully reversible, capable of undergoing only one 
aggregation-disaggregation-aggregation cycle. Furthermore, the cryo-TEM imaging 






Further studies on the MLV system are planned in order to elucidate the exact 
mechanism behind the formation of the multilamellar system exhibited in the work of 
English et. al. TEM experiments taken at various stages namely; after aggregation, 
immediately following disaggregation, and of the dialyzed material, will help to 
determine if there is indeed a return to the unilamellar phase after multilamellar 
formation. Furthermore, studies of the vesicles after dialysis will be obtained; 
specifically, determination of size, response to environmental changes and cryo-TEM. 
Hopefully this will elucidate mechanism behind the “reversible” process. Finally, it is 
possible that the increased size of vesicles with increasing ionic strength could result 
in a change in the assembled structure. If there is a new structure and it is in fact 


















All chemicals and solvents were purchased from commercial suppliers unless 
otherwise noted.  
Equipment 
Absorbance spectra was collected using CHEM2000-UV-vis-spectrometer, Ocean 
Optics, Inc. Average hydrodynamic radius was determined using dynamic light 
scattering (DLS) using a Photocor Complex Optical unit equipped with a 5mW laser 
633nm. All DLS measurements were taken at a 90° scattering angle and at 25°C. Size 
distribution, polydispersity index, and hydrodynamic radius of vesicle samples were 
determined using an autocorrelation function utilizing the instruments software 
(Photocor Software). Cryogenic transition electron microscope (TEM) images were 
taken using (JEOL JEM 2100 ).  
Zeta potentials were collected using Malvern Zetasizer at 25°C.  
Size exclusion chromatography (SEC) was performed using A column (5.5cm length, 
1.5cm diameter)  packed with Sephadex G-100 (Sigma) suspended in 18 MΩ 
Millipore H2O for initial vesicle preparation and 1M glucose for preparation of 
multilamellar vesicles.  
General Procedures 
Carbohydrate Assay 
To determine the amount of carbohydrate present in each fraction a standard phenol-
sulfuric acid assay was used. A 0.250mL aliquot of the vesicle containing SEC 
fraction was transferred to a separate test tube where 0.125mL of 0.530M aqueous 
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phenol (13.3 mmol) was added, followed by the addition of 0.625mL of concentrated 
H2SO4 (18M) directly to the liquid surface. Samples where then vortexed and allowed 
to sit at room temperature for 1h to permit color formation. Presence of carbohydrate 
was indicated by the formation of a yellow/ orange color. 0.250mL of ethanol was 
then added to the samples and vortexed again. After 10 min at room temperature the 
absorbance was measured at 490 nm.  
Dialysis 
1 mL of vesicle solution was added to dialysis tubing (Spectra/Por MW, 1,000) and 
stirred in 18 MΩ Millipore water. Water was exchanged twice (every 2hrs) and then 
allowed to stir overnight. Vesicle solution was removed the following day.  
NaCl/ Size Tests 
 A 4M stock solution of NaCl was prepared and then diluted to the desired 
concentrations. 100 μL of vesicle solution was added to .5mL of corresponding salt 
solution. The solution was allowed to sit at room temperature for 5 min. before taking 
DLS measurements. 
pH Studies 
 Solutions of the desired pH were prepared using concentrated HCl (12 M) and 
concentrated NaOH (19 M). 100 μL of vesicle solution was added to .5mL of 
corresponding solution and allowed to sit at room temperature for 5 min. before 
taking DLS measurements. 
Kinetics 
 To evaluate the potential differences in the glucose distribution a kinetic assay 
was used. The absorbance at 450 nm was monitored over time after the addition of 
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buffered Con A to vesicles conjugated with different mole fractions of C12-glucose.  
A blank containing 400 μL of vesicle sample and 100 μL buffer with no ConA was 
used in each experiment. Each run was performed by first adding 400 µL of vesicle 
sample to the cuvette, then placing the cuvette in the UV-vis spectrometer, adding 
100 µL of buffered Con A, then immediately starting acquisition of the kinetics data. 
The concentration of Con A used was 5 µM. For each kinetics run, the initial rate was 
found from the slope of the initial linear region of the absorbance plot. The initial rate 
of aggregation was monitored to avoid complications associated with a nonlinear 
response from the formation of large aggregates. 
Vesicle Preparation  
All vesicles were prepared with an excess of the anionic surfactant SDBS and are thus 
referred to as anionic vesicles.  
Method 1 
9.90 mL of 18 mΩ Millipore H2O was added to a vial containing of SDBS of CTAT, 
and C12-glucose adjusted for the desired w/w ratio of surfactants to C12-glucose. 
Solution was stirred for 1hr resulting in a milky colloid solution which was then 
further purified using size exclusion chromatography (SEC) 
Method 2 
 9.90 mL of 18 Ω Millipore H2O was added to a vial containing of SDBS and of 
CTAT. Solution was stirred for 1hr resulting in colloidal suspension of bare anionic 
vesicles. This solution was then added to a vial containing C12-glucose and stirred for 




9.90 mL of 18 Ω Millipore H2O was added to a vial containing C12-glucose. 
Solution was stirred until glucose was dissolved. The resulting solution was then 
added to a vial containing SDBS and CTAT adjusted for the desired w/w ratio. 
Solution was stirred for 1hr resulting in a colloidal suspension milky in appearance 
which was then further purified using SEC 
Method 4 
 9.90 mL of 18 mΩ Millipore H2O was added to a vial containing of 70.0 mg of 
SDBS, 30.0mg of CTAT, and the desired amount of C12-glucose adjusted for the 
desired w/w ratio of surfactants to glycoconjugate. Solution was stirred for 1hr 
resulting in a milky colloid solution which was then further purified using size 
exclusion chromatography (SEC) 
Method 5 
 9.90 mL of 18 Ω Millipore H2O was added to a vial containing 70.0 mg of SDBS 
and 30.0 mg of CTAT. Solution was stirred for 1hr resulting in colloidal suspension 
of bare anionic vesicles. This solution was then added to a vial containing the desired 
amount of C12-glucose and stirred for an additional hour which was then further 
purified using SEC 
Method 6 
9.90 mL of 18 Ω Millipore H2O was added to a vial containing the desired amount of 
n C12-glucose. Solution was stirred until glucose was dissolved. The resulting 
solution was then added to a vial containing 70.0 mg of SDBS and 30.0 mg of CTAT. 
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Solution was stirred for 1hr resulting in a colloidal suspension milky in appearance 
which was then further purified using SEC 
Multilamellar Vesicles 
To each of the previously formed vesicle solutions 0.200 mL of 5μM ConA was 
added, resulting in visible aggregation. Solutions were allowed to sit at room 
temperature for 45 min, after which 0.100 mL of 1M glucose was added. Solution 
was then stirred for 1h at room temperature resulting in a milky colloidal solution. 
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